Pharmaceutical marketing is undergoing a fundamental power shift toward healthcare professionals, and brands must rethink how and when they engage. In this executive interview, Joshua Alvernia, CEO and founder of Wrango, explains why gaining HCP consent and delivering value at the right clinical moment has become essential for building meaningful brand relationships.
Alvernia outlines why outcomes-based marketing remains difficult, citing the challenge of tying campaigns to prescribing behavior across fragmented platforms. He discusses the importance of consented identity, closed-loop measurement and integrating clinical signals to move beyond proxy metrics like impressions and clicks.
The conversation explores how modern infrastructure and data orchestration can help agencies reach providers when they are most receptive, not simply more often. By shifting focus from broad reach to moment-based relevance, Alvernia argues brands can break through the noise and drive outsized impact.
The editorial staff had no role in this post's creation.